Cisplatin-induced ototoxicity in patients receiving concurrent chemoradiation in carcinoma cervix
Background: Weekly cisplatin at 40mg/m2 is the most common regimen followed in our institution. However, patients receiving cisplatin can experience high-frequency hearing loss due to its expansive toxicity profile, a side effect known as ototoxicity. The dearth of information on the extent and sev...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KIMS Foundation and Research Center
2022-07-01
|
| Series: | Journal of Medical and Scientific Research |
| Subjects: | |
| Online Access: | http://jmsronline.com/archive-article/Cisplatin-induced-ototoxicity-chemoradiation-in-carcinoma-cervix |